Compare Edgewise Therapeutics Inc. Common Stock (EWTX) vs Oruka Therapeutics Inc. Common Stock (ORKA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Edgewise Therapeutics Inc. Common Stock vs Oruka Therapeutics Inc. Common Stock — how do they compare? Edgewise Therapeutics Inc. Common Stock trades at $37.32 (market cap $3.94B), while Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.18B). The key difference: Oruka Therapeutics Inc. Common Stock is the larger of the two by market cap, and Edgewise Therapeutics Inc. Common Stock is trading nearer its 52-week high, Oruka Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Edgewise Therapeutics Inc. Common Stock for 0 Days and Oruka Therapeutics Inc. Common Stock for 0 Days on average.
| EWTX | ORKA | |
|---|---|---|
Market Cap | $3.94B | $5.18B |
Volume | 810,104 | 490,798 |
Sector | Health | Health |
52-Week High | $48.35 | $113.08 |
52-Week Low | $14.89 | $26.19 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $3.48B | $4.31B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Edgewise Therapeutics Inc. Common Stock
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops small-molecule therapies based on its research in muscle physiology, with a pipeline focused on cardiovascular and cardiometabolic conditions such as hypertrophic cardiomyopathy and heart failure.
Read more on EWTX →About Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →
